Literature DB >> 25904126

Impact of clinical awareness and diagnostic tests on the underdiagnosis of Clostridium difficile infection.

L Alcalá1, E Reigadas, M Marín, A Martín, P Catalán, E Bouza.   

Abstract

A multicenter study of Clostridium difficile infection (CDI) performed during 2008 in Spain revealed that two of every three episodes went undiagnosed or were misdiagnosed owing to nonsensitive diagnostic tests or lack of clinical suspicion and request. Since then, efforts have been made to improve the diagnostic tests used by laboratories and to increase the awareness of this disease among both clinicians and microbiologists. Our objective was to evaluate the impact of these efforts by assessing the current magnitude of underdiagnosis of CDI in Spain using two point-prevalence studies performed on one day each in January and July of 2013. A total of 111 Spanish laboratories selected all unformed stool specimens received for microbiological diagnosis on these days, and toxigenic culture was performed at a central reference laboratory. Toxigenic isolates were characterized both pheno- and genotypically. The reference laboratory detected 103 episodes of CDI in patients aged 2 years or more. Half (50.5 %) of the episodes were not diagnosed in the participating laboratories, owing to insensitive diagnostic tests (15.5 %) or the lack of clinical suspicion and request (35.0 %). The main ribotypes were 014, 078/126, 001/072, and 106. Ribotype 027 caused 2.9 % of all cases. Despite all the interventions undertaken, CDI remains a highly neglected disease because of the lack of sensitive diagnostic tests in some institutions and, especially, the absence of clinical suspicion, mainly in patients with community-associated CDI. Toxigenic C. difficile should be routinely sought in unformed stools sent for microbiological diagnosis, regardless of their origin.

Entities:  

Mesh:

Year:  2015        PMID: 25904126     DOI: 10.1007/s10096-015-2380-3

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  34 in total

1.  Laboratory-acquired clostridium difficile polymerase chain reaction ribotype 027: a new risk for laboratory workers?

Authors:  Emilio Bouza; Adoración Martin; Renata J Van den Berg; Ed J Kuijper
Journal:  Clin Infect Dis       Date:  2008-12-01       Impact factor: 9.079

2.  C. Diff Quik Chek complete enzyme immunoassay provides a reliable first-line method for detection of Clostridium difficile in stool specimens.

Authors:  Criziel D Quinn; Susan E Sefers; Wisal Babiker; Ying He; Romina Alcabasa; Charles W Stratton; Karen C Carroll; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2009-12-02       Impact factor: 5.948

3.  The co-seasonality of pneumonia and influenza with Clostridium difficile infection in the United States, 1993-2008.

Authors:  Kevin A Brown; Nick Daneman; Paul Arora; Rahim Moineddin; David N Fisman
Journal:  Am J Epidemiol       Date:  2013-05-09       Impact factor: 4.897

Review 4.  Emergence of Clostridium difficile-associated disease in North America and Europe.

Authors:  E J Kuijper; B Coignard; P Tüll
Journal:  Clin Microbiol Infect       Date:  2006-10       Impact factor: 8.067

5.  What is the current role of algorithmic approaches for diagnosis of Clostridium difficile infection?

Authors:  Mark H Wilcox; Tim Planche; Ferric C Fang; Peter Gilligan
Journal:  J Clin Microbiol       Date:  2010-10-27       Impact factor: 5.948

6.  Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest.

Authors:  S S Wong; P C Woo; W K Luk; K Y Yuen
Journal:  Diagn Microbiol Infect Dis       Date:  1999-05       Impact factor: 2.803

7.  A prospective nationwide study of Clostridium difficile-associated diarrhea in Sweden. The Swedish C. difficile Study Group.

Authors:  O Karlström; B Fryklund; K Tullus; L G Burman
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

8.  Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates.

Authors:  Patrizia Spigaglia; Paola Mastrantonio
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

9.  Comparison of ImmunoCard Toxins A&B and the new semiautomated Vidas Clostridium difficile Toxin A&B tests for diagnosis of C. difficile infection.

Authors:  Luis Alcalá; Mercedes Marín; María Madrid; Esther Domínguez-García; Pilar Catalán; María Teresa Peláez; Mar Sánchez-Somolinos; Emilio Bouza
Journal:  J Clin Microbiol       Date:  2010-01-13       Impact factor: 5.948

10.  Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA.

Authors:  Preeta K Kutty; Christopher W Woods; Arlene C Sena; Stephen R Benoit; Susanna Naggie; Joyce Frederick; Sharon Evans; Jeffery Engel; L Clifford McDonald
Journal:  Emerg Infect Dis       Date:  2010-02       Impact factor: 6.883

View more
  12 in total

1.  Age and gender differences in Clostridium difficile-related hospitalization trends in Madrid (Spain) over a 12-year period.

Authors:  M D Esteban-Vasallo; S Naval Pellicer; M F Domínguez-Berjón; M Cantero Caballero; Á Asensio; G Saravia; J Astray-Mochales
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-04-07       Impact factor: 3.267

2.  An outbreak of Clostridium difficile PCR ribotype 027 in Spain: risk factors for recurrence and a novel treatment strategy.

Authors:  E Bouza; L Alcalá; M Marín; M Valerio; E Reigadas; P Muñoz; M González-Del Vecchio; V de Egea
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-05-13       Impact factor: 3.267

3.  Clostridioides difficile ribotype 106: A systematic review of the antimicrobial susceptibility, genetics, and clinical outcomes of this common worldwide strain.

Authors:  T J Carlson; D Blasingame; A J Gonzales-Luna; F Alnezary; K W Garey
Journal:  Anaerobe       Date:  2019-12-19       Impact factor: 3.331

4.  Variability in testing policies and impact on reported Clostridium difficile infection rates: results from the pilot Longitudinal European Clostridium difficile Infection Diagnosis surveillance study (LuCID).

Authors:  K Davies; G Davis; F Barbut; C Eckert; N Petrosillo; M H Wilcox
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-02       Impact factor: 3.267

Review 5.  Current knowledge on the laboratory diagnosis of Clostridium difficile infection.

Authors:  Adrián Martínez-Meléndez; Adrián Camacho-Ortiz; Rayo Morfin-Otero; Héctor Jesús Maldonado-Garza; Licet Villarreal-Treviño; Elvira Garza-González
Journal:  World J Gastroenterol       Date:  2017-03-07       Impact factor: 5.742

6.  Prevalence and molecular epidemiology of Clostridium difficile infection in Thailand.

Authors:  P Putsathit; M Maneerattanaporn; P Piewngam; P Kiratisin; T V Riley
Journal:  New Microbes New Infect       Date:  2016-10-21

7.  Impact of the introduction of a nucleic acid amplification test for Clostridium difficile diagnosis on stool rejection policies.

Authors:  J Goret; J Blanchi; P Floch; O Peuchant; D Chrisment; R Sanchez; H Biessy; R Lemarié; D Leyssene; B Loutfi; S Mimouni; T Flao; C Bébéar; F Mégraud
Journal:  Gut Pathog       Date:  2018-05-30       Impact factor: 4.181

8.  Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain.

Authors:  Miguel Salavert; Javier Cobo; Álvaro Pascual; Belén Aragón; Stefano Maratia; Yiling Jiang; Susana Aceituno; Santiago Grau
Journal:  Adv Ther       Date:  2018-10-16       Impact factor: 3.845

9.  Fecal Microbiota of Toxigenic Clostridioides difficile-Associated Diarrhea.

Authors:  Marta Hernández; Mónica de Frutos; David Rodríguez-Lázaro; Luis López-Urrutia; Narciso M Quijada; Jose María Eiros
Journal:  Front Microbiol       Date:  2019-01-14       Impact factor: 5.640

10.  Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR).

Authors:  E Bouza; J M Aguado; L Alcalá; B Almirante; P Alonso-Fernández; M Borges; J Cobo; J Guardiola; J P Horcajada; E Maseda; J Mensa; N Merchante; P Muñoz; J L Pérez Sáenz; M Pujol; E Reigadas; M Salavert; J Barberán
Journal:  Rev Esp Quimioter       Date:  2020-02-20       Impact factor: 1.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.